NASDAQ$ADVM
Adverum Biotechnologies Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Adverum reported financial results for the second quarter ended June 30, 2021.
Adverum Biotechnologies reported a net loss of $44.3 million for the second quarter of 2021. The company's cash, cash equivalents, and short-term investments were $363.8 million as of June 30, 2021, which is expected to fund operations into 2024.
- Adverum is prioritizing the development of ADVM-022 in wet age-related macular degeneration.
- Cash runway is extended into 2024 based on current development and manufacturing plans for ADVM-022.
- Long-term OPTIC data shows the potential for the low dose of ADVM-022 to offer durable treatment for wet AMD.
- Adverum is in active discussions to sublease its GMP commercial manufacturing facility in Research Triangle Park, NC.
Headline financials
Revenue & EPS history
Adverum · Revenue · Quarterly
$0
Forward guidance
Adverum anticipates presenting long-term OPTIC data in wet AMD and INFINITY data in DME in 2H21. They also plan to complete data analysis by YE21 to develop a protocol and seek feedback on a Phase 2 clinical trial in wet AMD.
Tailwinds
- Plan to present long-term OPTIC data in wet AMD in 2H21, including 52-week data from Cohort 4 at a medical conference
- Plan to present INFINITY data in DME in 2H21 at a medical conference
- Plan to complete data analysis by YE21 to develop a protocol
- Seek investigator and regulatory feedback on a Phase 2 clinical trial in wet AMD
- Evaluate low doses of ADVM-022 and alternative prophylactic regimens
Headwinds
- Adverum’s novel technology, which makes it difficult to predict the time and cost of product candidate development and obtaining regulatory approval
- The results of early clinical trials not always being predictive of future results
- The potential for Adverum’s recent announcement of a dose-limiting toxicity at the high dose in DME patients in our INFINITY trial
- Any future complications or side effects in connection with use of ADVM-022
- May delay or prevent regulatory advancement or approval for ADVM-022
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 15 quarterly earnings reports
+0.0%
Avg return
Earnings day
-0.8%
Avg return
5 days after
-2.5%
Avg return
30 days after
45%
17 / 38 earnings
Positive
+12.5%
Q3 2022
Best reaction
-15.5%
Q2 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | -0.9% | -1.2% | — | |
| Q2 2025 | +10.8% | +27.9% | +41.4% | |
| Q1 2025 | -1.0% | +21.0% | +19.5% | |
| Q4 2024 | -5.8% | -15.4% | -41.0% | |
| Q3 2024 | +4.2% | +8.4% | -18.5% | |
| Q2 2024 | +3.0% | +4.7% | +7.3% | |
| Q1 2024 | -5.2% | -9.3% | -25.1% | |
| Q4 2023 | -2.9% | -5.3% | -33.1% | |
| Q3 2023 | +1.8% | -3.4% | +0.0% | |
| Q2 2023 | +2.2% | -3.8% | -7.1% | |
| Q1 2023 | -4.6% | -4.1% | +89.3% | |
| Q4 2022 | -4.5% | -6.7% | +3.6% | |
| Q3 2022 | +12.5% | +3.2% | -9.6% | |
| Q2 2022 | -4.5% | -8.6% | -25.0% | |
| Q1 2022 | -14.1% | -13.5% | +2.7% | |
| Q4 2021 | -2.9% | -5.8% | -20.3% | |
| Q3 2021 | -5.6% | -1.3% | -24.9% | |
| Q2 2021 | +6.9% | — | — | |
| Q1 2021 | +3.3% | — | — | |
| Q4 2020 | -5.3% | — | — | |
| Q3 2020 | -7.8% | — | — | |
| Q2 2020 | -15.5% | — | — | |
| Q1 2020 | -1.9% | — | — | |
| Q4 2019 | +11.6% | — | — | |
| Q3 2019 | +8.9% | — | — | |
| Q2 2019 | -1.3% | — | — | |
| Q1 2019 | -3.7% | — | — | |
| Q4 2018 | +2.8% | — | — | |
| Q3 2018 | +1.9% | — | — | |
| Q2 2018 | +10.9% | — | — | |
| Q1 2018 | +3.6% | — | — | |
| Q4 2017 | -4.1% | — | — | |
| Q3 2017 | -6.3% | — | — | |
| Q2 2017 | -2.0% | — | — | |
| Q1 2017 | -1.8% | — | — | |
| Q3 2016 | +11.9% | — | — | |
| Q2 2016 | +2.3% | — | — | |
| Q3 2014 | +4.5% | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro